NCT06600711View on ClinicalTrials.gov

Nitazoxanide for Treatment of Cryptosporidium in Children

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

May 31, 2030

Conditions
Cryptosporidiosis
Interventions
DRUG

Nitazoxanide

5 mL suspension (100 mg), 2x/day for 3 days

DRUG

Placebo

identical in consistency, appearance, and taste to nitazoxanide suspension. 5 mL suspension given 2x/day for 3 days

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Johns Hopkins Bloomberg School of Public Health

OTHER